What is it about?
Pancreatic cancer (PC) is among the toughest cancers to treat, which calls for animal models to develop better diagnostic and therapeutic methods. To explain why primary PC is less responsive to vascular disrupting agent CA4P treatment than liver metastasis of PC, the present pancreatic head tumor model is created by orthotopic rhabdomyosarcoma implantation in rats. By using this model, that clinical phenomenon has been reproduced and its possible mechanisms are addressed [1]. Ref 1. Yin T, Liu Y, Peeters R, Feng Y, Yu J, Himmelreich U, Oyen R, and Ni Y. Vascular disrupting agent in pancreatic and hepatic tumor allografts: observations of location-dependent efficacy by MRI, microangiography and histomorphology. British Journal of Cancer 2017; 117:1529-36.
Featured Image
Why is it important?
See above.
Perspectives
Instead of vascular disrupting agents (VDAs) that could be highly effective on metastases, alternatives such as radiofrequency ablation, microwave ablation, highly intensive focused ultrasound etc. should be considered for treating inoperable pancreatic cancers, both primary and secondary.
Prof. Dr. Yicheng Ni
Associatie KU Leuven
Read the Original
This page is a summary of: Cover Image, Volume 30, Issue 2, NMR in Biomedicine, January 2017, Wiley,
DOI: 10.1002/nbm.3633.
You can read the full text:
Contributors
The following have contributed to this page
